Inverse probability of treatment adjusted Cox models of OS and lymphoma-specific survival based on the TRES score in NHL subtypes
| TRES score . | OS . | Lymphoma-specific survival . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | |||
| DLBCL | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.36 | 1.29 | 1.44 | 1.23 | 1.14 | 1.33 |
| 2-3 | 1.84 | 1.73 | 1.95 | 1.57 | 1.45 | 1.70 |
| FL | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.66 | 1.48 | 1.85 | 1.47 | 1.23 | 1.76 |
| 2-3 | 2.39 | 2.11 | 2.71 | 1.85 | 1.50 | 2.29 |
| Marginal zone lymphoma | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.49 | 1.31 | 1.71 | 1.09 | 0.84 | 1.42 |
| 2-3 | 2.10 | 1.81 | 2.43 | 1.38 | 1.03 | 1.86 |
| Mantle cell lymphoma | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.43 | 1.22 | 1.67 | 1.16 | 0.94 | 1.45 |
| 2-3 | 1.83 | 1.54 | 2.18 | 1.19 | 0.93 | 1.53 |
| Lymphoplasmacytic lymphoma | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.37 | 1.00 | 1.87 | 0.77 | 0.40 | 1.49 |
| 2-3 | 2.56 | 1.85 | 3.55 | 1.30 | 0.65 | 2.60 |
| CLL | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.47 | 1.36 | 1.58 | 1.24 | 1.08 | 1.42 |
| 2-3 | 2.19 | 2.02 | 2.37 | 1.27 | 1.07 | 1.50 |
| Peripheral T-cell lymphoma | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.35 | 1.15 | 1.57 | 1.20 | 0.99 | 1.46 |
| 2-3 | 1.63 | 1.38 | 1.93 | 1.19 | 0.95 | 1.49 |
| Cutaneous T-cell lymphoma | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.60 | 1.29 | 1.99 | 1.21 | 0.85 | 1.73 |
| 2-3 | 2.48 | 1.94 | 3.17 | 1.89 | 1.27 | 2.79 |
| TRES score . | OS . | Lymphoma-specific survival . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | |||
| DLBCL | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.36 | 1.29 | 1.44 | 1.23 | 1.14 | 1.33 |
| 2-3 | 1.84 | 1.73 | 1.95 | 1.57 | 1.45 | 1.70 |
| FL | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.66 | 1.48 | 1.85 | 1.47 | 1.23 | 1.76 |
| 2-3 | 2.39 | 2.11 | 2.71 | 1.85 | 1.50 | 2.29 |
| Marginal zone lymphoma | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.49 | 1.31 | 1.71 | 1.09 | 0.84 | 1.42 |
| 2-3 | 2.10 | 1.81 | 2.43 | 1.38 | 1.03 | 1.86 |
| Mantle cell lymphoma | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.43 | 1.22 | 1.67 | 1.16 | 0.94 | 1.45 |
| 2-3 | 1.83 | 1.54 | 2.18 | 1.19 | 0.93 | 1.53 |
| Lymphoplasmacytic lymphoma | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.37 | 1.00 | 1.87 | 0.77 | 0.40 | 1.49 |
| 2-3 | 2.56 | 1.85 | 3.55 | 1.30 | 0.65 | 2.60 |
| CLL | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.47 | 1.36 | 1.58 | 1.24 | 1.08 | 1.42 |
| 2-3 | 2.19 | 2.02 | 2.37 | 1.27 | 1.07 | 1.50 |
| Peripheral T-cell lymphoma | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.35 | 1.15 | 1.57 | 1.20 | 0.99 | 1.46 |
| 2-3 | 1.63 | 1.38 | 1.93 | 1.19 | 0.95 | 1.49 |
| Cutaneous T-cell lymphoma | ||||||
| 0 | — | — | — | — | — | — |
| 1 | 1.60 | 1.29 | 1.99 | 1.21 | 0.85 | 1.73 |
| 2-3 | 2.48 | 1.94 | 3.17 | 1.89 | 1.27 | 2.79 |